Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia Granted Patent for CEfrag™ Drug Discovery Platform

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
CEfrag™ platform uses capillary electrophoresis to identify fragment compounds.

Selcia Limited has been granted a UK patent for the technology platform underpinning the company’s CEfrag™ drug screening service.

Titled “Capillary electrophoresis method for assessing the binding of chemical compounds to biological targets”, the patent relates to the screening of compound libraries against specific targets, in particular screening for weak-binding ligands.

Numbered GB 2481168, the patent was filed 20 September 2010 and granted 27 June 2012.

The patenting of Selcia’s CEfrag technology is the culmination of a three year plan by Selcia to build a fully integrated drug discovery division alongside its existing 14C radiochemistry service.

The newly patented technology was first unveiled by Selcia following the acquisition of IP and expertise from Cetek Corporation in 2009.

Further technical development of the fragment screening platform resulted in the launch of CEfrag the following year with a fragment library of 1,500 compounds.

CEfrag has generated a great deal of interest amongst pharmaceutical and biotech organizations and this has already resulted in a number of collaborations including a recent deal with Heptares, a UK-based biotech company that discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors) The goal of this collaboration was to identify fragment ligands that specifically bind to a Heptares GPCR drug target.

Selcia’s CEfrag™ platform uses capillary electrophoresis to identify fragment compounds that selectively bind to drug targets.

A significant advantage of this approach is that all reagents are in solution and no tethering of the protein is required, enabling near physiological ligand/target interactions to be observed with a low false positive rate.

The technology can be used to detect fragment/target interactions across a wide range of target classes including “challenging” targets such as protein-protein interactions.

The technology can also be used to screen natural extracts for novel druggable natural compound starting points for drug discovery programmes, an area in which Selcia specializes.

Simon Bury, Business Development Director - Discovery, Selcia, comments: “The CEfrag drug screening platform has already shown itself to be a novel, scientifically robust approach to drug discovery. By patenting the technology we have demonstrated our strong intent to build a differentiated technology platform that will sit at the heart of Selcia’s integrated drug discovery service capabilities”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia Appoints New Director of Discovery
Appointment of John Davis to the role of Director of Discovery.
Wednesday, October 09, 2013
Selcia and Heptares Therapeutics Announce New Fragment Screening Collaboration
Partnership to utilize Selcia’s CEfrag™ capillary electrophoresis fragment screening technology.
Thursday, April 19, 2012
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!